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Natural killer (NK) cells are innate immune lymphocytes critical for host defense against
viral infection and surveillance against malignant transformation. MicroRNAs (miRNAs) are
a family of small, non-coding RNAs that regulate a wide variety of cellular processes.
Recent advances have highlighted the importance of miRNA-mediated post-transcriptional
regulation in NK cell development, maturation, and function. This review focuses on
several facets of this regulatory mechanism in NK cells: (1) the expressed NK cell miRNA
transcriptome; (2) the impact of total miRNA deﬁciency on NK cells; (3) the role of speciﬁc
miRNAs regulating NK cell development, survival, and maturation; (4) the intrinsic role
of miRNAs regulating NK cell function, including cytokine production, proliferation, and
cytotoxicity; and (5) the role of NK cell miRNAs in disease. Currently our knowledge of how
miRNAs regulate NK cell biology is limited, and thus we also explore key open questions in
the ﬁeld, as well as approaches and techniques to ascertain the role of individual miRNAs
as important molecular regulators.
Keywords: microRNA, miRNA, natural killer

INTRODUCTION
Natural killer (NK) cells are innate immune lymphocytes that
develop from the common lymphoid progenitor in the bone marrow; however, NK cells are deﬁned by a unique biological program
that is distinct from the adaptive T and B lymphocytes which
develop from that same progenitor (Yokoyama et al., 2004). NK
cell development proceeds through a series of intermediates that
are dependent on growth factors and cytokines, distinct from B
and T cell development, to support their development and homeostasis, especially IL-15 (Colucci et al., 2003; Freud and Caligiuri,
2006). Furthermore, NK cells reconstitute after hematopoietic
stem cell transplantation more rapidly than other lymphocytes
(Storek et al., 2008), further attesting to their uniqueness as a lymphoid lineage. However, although the distinctions between NK
cells and other lymphocytes are well known, the molecular events
and programs that deﬁne NK cells are incompletely understood,
and remain an important area of NK cell investigation.
In mice, NK cells are identiﬁed as lymphocytes that express
two activating receptors: NK1.1 (C57Bl/6) and NKp46 (virtually
all mouse background strains), and lack CD3 and CD19 expression (Colucci et al., 2003). In humans, NK cells are distinguished
by their expression of CD56, and a lack of CD3 and rearranged
T cell receptors. NK cells begin their development in the bone
marrow, where they are subject to an education process, in which
the NK cells are licensed to full functionality by becoming tuned
to the “normal” levels of cell surface ligands, primarily major
histocompatibility complex (MHC) class I or related molecules
(Joncker and Raulet, 2008; Jonsson and Yokoyama, 2009). Murine
NK cells undergo further maturation in peripheral lymphoid
organs, marked by expression of CD27, CD11b, and CD43
(Chiossone et al., 2009). Human NK cells in the periphery may
further be divided into subsets by their expression of CD56 and
CD16 (FCγRIIIa): the functionally and developmentally distinct
CD56bright and CD56dim populations (Caligiuri, 2008).
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Mature peripheral NK cells defend the host from pathogens and
mediate anti-tumor responses (Yokoyama et al., 2004; Caligiuri,
2008; Di Santo, 2008; Lanier, 2008). One way that NK cells protect the host is by detecting abnormal surface receptor repertoires
on target cells, through loss of self-deﬁning proteins and/or gain
of abnormal or induced self-proteins. Typical inhibitory NK cell
receptor ligands include MHC class I molecules, which are often
down-regulated on target tumor and infected cells, and “stress”
ligands such as retinoic acid early inducible-I (Rae-I) and UL16
binding protein 1 (ULBP1), which can activate NK cells and are
often up-regulated on these target cells. It is the relative levels
of these inhibitory and activating signals that determine whether
or not the NK cell is triggered to respond to a potential target
cell (Lanier, 2005; Bryceson and Long, 2008). Once triggered,
NK cells then mediate cytotoxicity against these cells through the
release of cytotoxic granules, as well as produce various cytokines
and chemokines that inﬂuence the developing immune response
(Vivier et al., 2008). In addition to responding to ligands on target
cells, NK cells express a number of cytokine receptors and can be
activated or primed by pro-inﬂammatory cytokines for optimal
effector function. Cytokine activation can also override inhibition
mediated by some cell surface signals, and thus represents another
important signal for NK cell functional capacity (Fehniger et al.,
2007; Lee et al., 2007; Lucas et al., 2007; Caligiuri, 2008; Chaix
et al., 2008).
Currently, our understanding of the basic molecular mechanisms regulating NK cell development, maturation, survival, and
function is incomplete. A number of transcription factors have
been identiﬁed that contribute to NK cell development and function (Ramirez and Kee, 2010; Hesslein and Lanier, 2011). Recently,
studies have highlighted the role of post-transcriptional control,
especially microRNAs (miRNAs), on the NK cell molecular program (Fehniger et al., 2007; Bezman et al., 2010; Sullivan et al.,
2012). In this review, we highlight the current state of the ﬁeld in
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miRNA-mediated control of NK cell development, survival, maturation, with a focus on global and speciﬁc miRNA deﬁciency and
over-expression. As our knowledge of the molecular programs,
including miRNAs, that regulate NK cells increases, this will lead
to identiﬁcation of novel molecules and pathways that may be
manipulated to enhance or attenuate NK cell function.

MicroRNAs
MicroRNAs are non-coding RNAs, many of which are highly
conserved and regulate numerous cellular functions. miRNA
repression is mediated primarily by targeting sites in the 3 UTR
of mRNAs, leading to translational inhibition or causing mRNA
degradation (He and Hannon, 2004). One report has indicated
that some miRNAs can increase protein expression via binding to
the 5 UTR (Vasudevan et al., 2007), but it remains unclear whether
this is widely applicable.
Over 1,000 miRNA genes are predicted in humans and mice.
miRNAs can be processed in a variety of ways (Winter et al.,
2009), but the canonical pathway (Figure 1) consists of transcription from genomic sequence as long primary (pri-miRNA)
transcripts that are “cropped” by the Drosha/Dgcr8 complex into
precursor miRNAs (pre-miRNA) that have a characteristic stemloop structure (Kim, 2005). The pre-miRNA is exported to the
cytoplasm where it is “diced” by the Dicer complex (including
Dicer1) into a mature 19–26 nucleotide miRNA. The mature
miRNA is loaded into the RNA-induced silencing complex (RISC)
that includes the Argonaute proteins, and thereby directs downregulation of protein levels (Filipowicz et al., 2008; Liu, 2008; Wu
and Belasco, 2008). While the exact mechanism of protein reduction remains controversial, it is likely that it occurs through both

FIGURE 1 | Summary of canonical miRNA biogenesis and function.
DNA (1) is transcribed by PolII into the pri-miRNA (2), which is then further
processed by Drosha/DGCR8 into the pre-miRNA (3). This pre-miRNA is
exported from the nucleus through exportin 5, then processed by Dicer to the
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RNA degradation and translational repression pathways, perhaps
with different miRNAs contributing to each pathway in different proportions. While perfect miRNA:mRNA complementarity
(common in C. elegans) can lead to direct mRNA degradation,
most miRNAs in higher organisms are imperfectly matched, and
lead to mRNA degradation through deadenylation and decapping
methods (Liu, 2008). Both processes are mediated by the “stem”
of the “stem-loop,” the critical segment of the miRNA gene.
The role of miRNA-mediated regulation in antigen-speciﬁc T
and B lymphocytes is well characterized. In these cells, development, survival, and function have been found to be controlled
by miRNAs, data which are clearly supported by mouse models
of miRNA gain- and loss-of-function (O’Connell et al., 2010b).
While the data supporting critical regulation of NK cells by
miRNAs are more exiguous (Di Santo, 2008), this review synthesizes recent studies that have provided the ﬁrst insights into
the expressed mouse and human NK cell miRNA transcriptome
and mechanisms whereby miRNAs regulate NK cell development,
homeostasis, and functional responses.

THE NK CELL microRNA TRANSCRIPTOME
In contrast to T and B lymphocytes, there are few studies examining the miRNA proﬁles of human or mouse NK cells. The majority
of studies that include NK cell expression data have focused on
lymphocyte-wide comparisons, with an emphasis on identifying
miRNAs with cell-speciﬁc functions (Landgraf et al., 2007; Rossi
et al., 2011; Allantaz et al., 2012). As a result, many of these studies
utilize miRNA microarrays or Sanger sequencing of small RNA
clones. While these approaches provide the coverage necessary
for identifying miRNA “signatures,” there is comparatively less

mature miRNA duplex (4). This duplex is unwound, and one strand, the
mature miRNA, is loaded into the RISC complex (5), where it usually binds
imperfectly to a target mRNA and mediates RNA degradation and/or
translational repression.
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miRNA detection depth and and/or dynamic range relative to
unbiased next-generation small RNA sequencing. Additionally,
next-generation sequencing provides novel miRNA identiﬁcation,
although at the tradeoff of higher cost per sample. Ideally, any
accurate and reliable proﬁling data would utilize cross-platform
validation of multiple biological samples.
To date, three studies have utilized next-generation sequencing
to probe mouse or human NK cell miRNA expression (Figure 2).
We identiﬁed the resting and 24-h IL-15-activated proﬁle of
murine splenic NK cells (Fehniger et al., 2010). This revealed
that while >200 miRNAs were detectable in NK cells, the top
50 constituted >95% of the miRNA sequence content. The
miRNA expression proﬁle was supported by two independent
next-generation sequencing platforms (Illumina and SOLiD), with
validation by qPCR and microarrays. Overall, the expression
of normalized miRNA read counts was similar between resting
and 24-h IL-15-activated NK cells, with a small number of miRNAs signiﬁcantly modulated, peaking around threefold. It will be
important to extend these proﬁling studies to different types of

FIGURE 2 | Mouse and human NK cell miRNA expression.
(A) The top 30 miRNAs detected by Illumina sequencing in mouse
splenic NK cells (Fehniger et al., 2010). (B) Top expressed miRNAs
detected and enumerated by small RNA Illumina sequencing of resting
human CD56+ CD3− in the Wang et al.’s 2012 study. (C) Top expressed
miRNAs detected by small RNA Illumina sequencing in the Liu et al.’s 2012
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mouse NK cells, including developmental and maturation intermediates, NK cells from distinct tissue compartments, and in
the context of physiologic responses to infectious pathogens and
tumor cells. A larger, more robust set of miRNA expression proﬁles
will also facilitate comparison to other lymphocytes, and identify NK cell miRNA signatures which likely contribute to an NK
cell-speciﬁc molecular program.
Two subsequent studies by Liu and colleagues and Wang and
colleagues reported the miRNA proﬁles of resting and interferonα (IFN-α; Wang et al., 2012), IL-2, IL-15, and IL-21 (Liu et al.,
2012) activated bulk CD56+ CD3− human NK cells from peripheral blood. The resting human NK cell data sets show substantial
variation from each other, thus indicating that human diversity
may also be an important consideration during expression studies. Indeed, both groups that have reported human NK expression
include data from only one resting human sample, which limits
conclusions that can be drawn from comparing these particular data sets to each other. Additionally, the proﬁling from Wang
et al. (2012) is challenging to compare to the other studies, since

study. The Wang et al.’s 2012 and Liu et al.’s 2012 data are limited to the
miRNAs reported in the published paper, since the numerical data
was not provided in supplemental ﬁles nor deposited in public databases.
Liu et al.’s 2012 data were estimated from graphs included in the original
paper. 1 miRNA not reported in Liu et al. (2012). 2 miRNA not reported in Wang
et al. (2012).
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only the top 12 miRNAs were reported outside of their private
activation-based analysis. Following activation, human NK cells
appear to modestly up-regulate nearly half of all expressed miRNAs in response to IL-15, although these data rely on comparisons
of resting and activated cells from separate donors (Table 1).
The miRNAs that changed with activation demonstrated minimal overlap, suggesting activation-speciﬁc modulation or donor
variation. Interestingly, NK cells activated with IFN-α respond by
down-regulating a number of miRNAs, suggesting that miRNA
changes are dependent on the mode of stimulation. Such global
changes in miRNA may also reﬂect time point of measurement or
normalization biases, since the absolute miRNA content of a cell
can remain unchanged even as other small RNA content increases.
Indeed, 12-h IFN-α-activated NK cells had a 2.5-fold increase in
non-miRNA small RNA content (Wang et al., 2012).
From the Fehniger et al.’s (2010) and Wang et al.’s (2012) data,
miRNA expression patterns common to both human and mouse
NK cells are evident, with miR-21 being the most highly expressed
miRNA in both studies. However, there are relative abundance
differences, even among highly expressed miRNAs. One potential conclusion is that miRNAs have species-speciﬁc expression
patterns in NK cells. However, such cross-study comparisons
of absolute abundance are difﬁcult, since the reported human
miRNA expression proﬁles were from peripheral blood NK cells
from a single human donor, and the mouse proﬁling focused
on splenic NK cells. Further, there may be technical differences
in alignment, sequence ﬁltering, and normalization. Contrasting mouse and human NK cell miRNA expression will require
additional data from each species, ideally performed using similar
sequencing-analysis pipelines.
In summary, while the basic resting NK cell miRNA transcriptomes have been reported, our knowledge remains incomplete in
both mouse and human NK cells, hampered in part by a lack of
extensive cross-platform validation across biological replicates. A
number of questions are yet to be answered. Do different subsets

Table 1 | Selected up- or down-regulated miRNAs during cytokine
activation of NK cells.
Fehniger et al.

Wang et al.

Liu et al. (2012)

(2010) (mouse)

(2012) (human)

(human)

Stimulation

IL-15

IFN-α

IL-2, IL-15, or

Duration (hour)

24

12 or 24

36

Up-regulated

mmu-miR-188-5p

IL-21

mmu-miR-339-5p hsa-let-7b

hsa-miR-15a

mmu-miR-19a

hsa-miR-155

Down-regulated mmu-miR-223

hsa-miR-378

mmu-miR-26b

hsa-miR-103

hsa-miR-1246

mmu-miR-181a

hsa-miR-30e

hsa-miR-331-3p

miRNAs were selected based on the following criteria: top threefold change
within the top 12 expressed miRNAs (Wang et al., 2012), signiﬁcant miRNAs
consistently changed by the listed stimulation (Liu et al., 2012), and top threefold
change (Fehniger et al., 2010).

Frontiers in Immunology | NK Cell Biology

(e.g., CD56bright and CD56dim ) differ in their miRNA proﬁles?
Does maturation stage and mode of activation affect miRNA
expression? Do NK cells from different cell compartments (e.g.,
thymic, splenic, lung, intestine, liver, etc.) express different miRNAs? Do miRNAs differ between different innate lymphoid cells
(Spits and Di Santo, 2011)? Further studies are needed to understand how miRNAs are induced in NK cells, the kinetics of miRNA
alterations, and the effects of perturbed miRNA expression on
target genes.

THE IMPACT OF TOTAL miRNA DEFICIENCY ON NK CELLS
Because many miRNAs are expressed by NK cells (Fehniger et al.,
2010), knockout of critical miRNA processing genes, including
Drosha/DGCR8 and Dicer1 (Figure 1) is one approach to study
the effects of “global loss” of miRNAs. The ﬁrst studies of miRNA
in lymphocytes utilized Dicer1 knockout mice to eliminate all
Dicer1-dependent miRNAs, and were focused on T cells (Muljo
et al., 2005; Chong et al., 2008). These studies reported that the
global knockout of miRNA led to increased IFN-γ production,
and increased activation, albeit with a severe reduction in cellular count and proliferation. Similarly, studies focused on NK cells
have found comparable results (Table 2), with a few important
differences.
The ﬁrst model to investigate the ramiﬁcations of small RNA
deletion in NK cells was an inducible (estrogen receptor, ER) Cre
model combined with LoxP-ﬂanked Dicer1 and DGCR8 alleles
reported by the Lanier laboratory (Bezman et al., 2010). This
strategy eliminated miRNAs in all cells in the mouse following
tamoxifen treatment. Focusing on the impact of this miRNA loss
on NK cells revealed increased NK cell apoptosis in the periphery,
combined with a selective loss of more mature CD11b+ CD27− NK
cells, and a reduction in surface expression of the activating NK
cell receptor NKG2D. These ﬁndings were coupled with reduced
IFN-γ production and CD107a surface expression following stimulation with anti-NK1.1, anti-Ly49H, and anti-NKp46, but not
stimulation with cytokines such as IL-12 and IL-18. The authors
therefore concluded that miRNAs are essential regulators of NK
cell development and immunoreceptor tyrosine-based activation
motif (ITAM)-based stimulation of NK cells. The authors also
found that miRNA-deﬁcient Ly49H+ NK cells robustly proliferated in response to murine cytomegalovirus (MCMV) infection,
but did not survive, and thus were not able to function in an effective NK cell MCMV response. However, these results may have
confounding factors inﬂuenced by the NK-extrinsic nature of the
ER-Cre model, which results in global mature miRNA loss in all
cells in the organism.
A study from our laboratory utilized a more speciﬁc Cre model
(restricted to lymphocytes) to investigate the results of Dicer1dependent miRNA loss (Sullivan et al., 2012). We used a hCD2-Cre
transgene (de Boer et al., 2003), which expresses Cre from the earliest stages of NK cell development in the bone marrow. Thus,
in these experiments Dicer1 was removed from NK cells [marked
by concurrent yellow ﬂuorescent protein (YFP) expression (Sullivan et al., 2012)] during the earliest stages of development,
and in a lymphocyte-restricted fashion. While this method was
not completely NK cell speciﬁc, it removes many potential
confounders by providing Dicer1-competent hematopoietic and

February 2013 | Volume 4 | Article 44 | 4

“ﬁmmu-04-00044” — 2013/2/26 — 16:00 — page 4 — #4

Sullivan et al.

MicroRNA regulation of natural killer cells

Table 2 | Summary of global miRNA-deficient (Dicer1−/− and DGCR8−/− ) or over-expression (Eri1−/− ) NK cells.
Sullivan et al. (2012)

Bezman et al. (2010)

Thomas et al. (2012)

Cre model

hCD2-Cre

ER-Cre

Global knockout

Gene

Dicerﬂ/ﬂ

Dicerﬂ/ﬂ /DGCR8ﬂ/ﬂ

Eril−/−

Effect on miRNAs

↓

↓

↑

Survival

↓

↓

∼

Proliferation

↓

↓

↓

# NK cells

↓*

↓*

↓*

IFN-γ production

↑

↓!

↓!

CD107a

↑

↓

∼

Receptor repertoire alterations

None observed

↓NKG2D

Multiple, especially ↓Ly49H/D

MCMV response

↑IFN-γ production

∼IFN-γ production ↓Ly49H+ NK cells

∼IFN-γ production ↓Ly49H+ NK cells

In vitro cytotoxicity

N/A

N/A

∼

*In particular, at latest stages of NK cell maturation. ! In response to activating (ITAM) receptor-mediated stimulation.

non-hematopoietic cells. This model conﬁrmed the reduced numbers and percentages of NK cells shown in the Bezman et al.’s
(2010) study, and reduced in vitro survival and proliferation, indicating that NK cell development and homeostasis are critically
regulated by miRNAs. However, in contrast to the Bezman et al.’s
(2010) study, hCD2-Cre × Dicer1ﬂ/ﬂ NK cells produced more
IFN-γ and had enhanced degranulation (CD107a surface expression) in response to multiple activating stimuli. These effects were
also apparent in Dicer1ﬂ/wt mice, showing that even decreased
Dicer1 levels can have a functional consequence on NK cell biology. Further, these ﬁndings in hCD2-Cre mice were corroborated
by increased IFN-γ production in vivo during MCMV infection.
The different phenotypes in these models likely reﬂect different
Cre-excision speciﬁcity and timing. Recently, NK cell-speciﬁc Cre
models driven by the NKp46/Ncr1 promoter in a bacterial artiﬁcial
chromosome (BAC) transgene (Eckelhart et al., 2011), or knock-in
(Narni-Mancinelli et al., 2011) have been reported. Thus, the tools
are ﬁnally available to deﬁnitively evaluate the cell-intrinsic effects
of both global and speciﬁc miRNA loss- and gain-of-function in
NK cells.
Another study by Thomas et al. (2012) focused on Eri1, an
exoribonuclease that degrades miRNAs and thus functions as a
negative regulator of miRNA-mediated control, and the effects of
its loss on NK and T cells. The authors found that Eri1-deﬁcient
NK and T cells displayed an increase in total miRNA abundance.
NK cells seemed particularly susceptible to the effects of Eri1 loss,
and displayed decreased percentage and numbers, especially at
the latest stages of development. The Eri1-deﬁcient NK cells displayed an altered cell receptor repertoire, including altered Ly49H
expression. In addition, while Eri1−/− NK cells did not show a
defect in IFN-γ production in response to IL-12 and IL-18, they
produced less IFN-γ in response to ITAM-dependent activating
receptors. Eri1-deﬁcient NK cells also displayed decreased proliferation in response to MCMV infection, with increased viral titers,
demonstrating the importance of Eri1 (probably due to miRNA
alterations) in the context of viral infection. While Eri1-deﬁcient
NK cells have changes in global miRNA expression and a clear
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development, maturation and functional phenotype, one caveat
to these ﬁndings acknowledged by the authors is that other RNA
species are affected by Eri1, thereby providing alternative explanations for the NK cell phenotype. In any case, this study clearly
implicates Eri1-mediated RNA processing in NK cell development
and functional responses, probably reﬂective of global miRNA
changes in NK cells.
Thus, the preponderance of evidence suggests that miRNAs
promote cellular survival, maturation, and proliferation, while
suppressing the production of key immune cytokines such as
IFN-γ. However, the study by Thomas et al. (2012) suggests that
miRNA-mediated repression of genes is required in both directions, i.e., increased miRNA expression can also affect NK cell
homeostasis, supporting a role of miRNAs as “tuners” of cellular
homeostasis. The effects of total miRNA elimination or increase
on speciﬁc functions of NK cells, however, are difﬁcult to extricate
from effects on survival, and thus studying the cell-intrinsic effects
of individual miRNAs in NK cells will, in the future, be a more
productive approach to identifying the effects, targets, and mechanisms of speciﬁc miRNAs. One key caveat to these global miRNA
alteration studies is that the models utilized are not NK cell speciﬁc and may affect progenitors and mature NK cells at different
points in development/differentiation, as well as cells that interact with NK cells. Combining NK cell-speciﬁc Cre models that
are now available (Eckelhart et al., 2011; Narni-Mancinelli et al.,
2011) with miRNA ﬂoxed alleles will provide important conﬁrmatory studies of how both global deﬁciency and speciﬁc miRNA
alterations regulate NK cell biology.

miRNA REGULATION OF NK CELL DEVELOPMENT
Like other hematopoietic cells, NK cells originate from stem cells
within the bone marrow. As they develop, they require the expression of a number of signaling proteins and transcription factors
essential for the NK lineage (Colucci et al., 2003; Yokoyama et al.,
2004; Di Santo, 2006; Freud and Caligiuri, 2006). As discussed
previously, Dicer1 deﬁciency in NK cells results in altered NK
cell development; however, few studies have examined the role
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of speciﬁc miRNAs. To date, two miRNAs and their targeted
molecules have been implicated in this process: miR-150 targeting
c-Myb, and miR-181a/b targeting NEMO-like kinase (NLK).
miR-150 is a lymphocyte-restricted miRNA, and its expression
correlates with cell maturity, suggesting a role in development
(Monticelli et al., 2005). In mice, miR-150 expression acts as a
ﬁne-tuner of B cell production through the targeting of c-Myb, a
transcription factor involved in hematopoiesis (Xiao et al., 2007;
Zhou et al., 2007). In contrast, miR-150 over-expression only modestly reduces mature T cell numbers, in part through c-Myb and
possibly Notch3, a receptor involved in thymocyte development
(Ghisi et al., 2011). Bezman et al. (2011) reported that miR150−/− mice have a deﬁciency of mature NK cells resulting from
defects in maturation and proliferation, and additionally that mice
over-expressing miR-150 had an accumulation of mature, hyperfunctional NK cells. This phenotype was mimicked by c-Myb+/−
mice, the putative target of miR-150.
Two miR-181 family members, miR-181a and miR-181b, are
also expressed in lymphocytes in a stage-speciﬁc manner. Overexpression in murine models results in increased B cell (Chen et al.,
2004) and T cell numbers (Li et al., 2007). Using an in vitro NK
cell differentiation system, Cichocki et al. (2011) demonstrated
that miR-181 expression increases in parallel with the maturation
stages of human NK cells. In vitro differentiation of CD34+ progenitor cells transduced by lentivirus engineered to over-express
miR-181a enhanced the development of CD56+ NK cells. One
possible mechanism for this effect is through targeting of NLK, a
negative regulator of the Notch pathway, which is essential for lymphocyte development. Notch signals have been shown to support
in vitro human NK cell differentiation (Bachanova et al., 2009;
Beck et al., 2009; Haraguchi et al., 2009), and this work demonstrates a role for miR-181 family members in regulating NK cell
development, possibly through modulating NLK and Notch in
lymphoid or NK cell progenitors. It will be important to further
assess miR-181a/b, as well as other miRNAs that change in expression during NK cell maturation, for additional mRNA targets and
impact on NK cell development and maturation.

miRNA REGULATION OF NK CELL FUNCTION
Cytotoxicity is a major function of NK cells, and multiple studies have investigated miRNA regulation of this pathway. Work
on miRNAs regulating cytotoxicity has focused on the two major
granule proteins, granzyme B (GzmB) and perforin (Prf1). Studies from our laboratory identiﬁed that both GzmB and Prf1
mRNA transcript was readily produced in resting murine NK
cells, and was only modestly up-regulated following IL-15 activation (Fehniger et al., 2007). This was in contrast to protein levels
and cytotoxic capacity, which both increased dramatically during activation, suggesting a post-transcriptional mechanism of
regulation.
Four recent studies have identiﬁed miRNAs regulating GzmB
and Prf1 in NK cells (Figure 3). In studies from our lab, miR223 was found to target the murine GzmB 3 UTR, and identiﬁed
as the most down-regulated miRNA following IL-15 treatment,
which we hypothesized could lead to increased GzmB production
after activation (Fehniger et al., 2010). However, NK cells from
miRNA-223−/− mice (Johnnidis et al., 2008) appear to express
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FIGURE 3 | Schema of recent studies demonstrating the role of
miRNAs in repression of cytotoxicity by NK cells.

similar amounts of GzmB as wild type mice at baseline, and exhibit
levels of cytotoxicity similar to wild type controls, suggesting that
miR-223 alone does not play a non-redundant role in limiting
murine GzmB translation in resting mouse NK cells (Leong and
Fehniger, unpublished data). Additional studies are still needed to
determine the impact of miR-223 gain- and loss-of-function, in
combination with other miRNAs, in primary NK cells.
In a second study, Kim et al. (2011) used in vitro differentiated
human NK cells (CD34+ hematopoietic progenitors cultured for
several weeks in NK cell differentiating conditions) to demonstrate
that miR-27a-5p (miR-27a*) targeted the 3 UTRs of both GzmB
and Prf1. This group observed reduced GzmB and Prf1 protein
with miR-27a-5p over-expression in this system (Kim et al., 2011).
Activation with IL-15 paradoxically leads to up-regulation of this
miRNA, possibly serving as a negative feedback loop on GzmB
and Prf1 production. Indeed, inhibition of miR-27a-5p in these
differentiated NK cells resulted in enhanced in vitro killing and
tumor protection in a xenograft model. However, the miRNA and
mRNA expression of in vitro differentiated NK cells that result
from long-term culture with high levels of activating cytokines
may be signiﬁcantly different than freshly isolated primary human
NK cells. miR-27a-5p (miR-27a*) is expressed at very low levels
in resting mouse (Fehniger et al., 2010) and human NK cells (Liu
et al., 2012), suggesting a more limited role for this miRNA outside
of extensive cytokine activation or ex vivo culture. Conﬁrmatory
studies using freshly isolated NK cells would be helpful to verify
the role of miR-27a-5p outside the context of extensive ex vivo
culture.
In the third study, Gong et al. (2012) show a role for miR-30c1* in targeting HMBOX1 and regulating cytotoxicity. The authors
use the human NK cell line (NKL), and showed that stimulation
through NKG2D led to down-regulation of a number of miRNAs
(Gong et al., 2012). One of these miRNAs, miR-30c-1-3p (miR30c-1*), targeted HMBOX1, an inhibitory transcription factor of
cytokine secretion. Over-expression or inhibition of miR-30c-13p resulted in altered killing against two hepatoma cell lines. As
in the previous study, it will be important to further elucidate the
role of miR-30c-1* in primary NK cells.
In the fourth study, Wang et al. (2012) demonstrate a role for
miR-378 and miR-30e in repressing baseline protein expression of
GzmB and Prf1, respectively. In contrast to the GzmB and Prf1
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suppression model of miR-27a-5p, mature miR-378 and miR-30e
expression is reduced upon IFN-α stimulation, releasing repression of GzmB and Prf1 and enhancing the cytotoxicity of NK cells.
Expression of both miRNAs was shown to be inversely correlated
with GzmB and Prf1 protein production. Further, nucleofection
of miRNA sponges against either miRNA-378 or miR-30e in NK92 cells led to enhanced cytotoxicity against K562 tumor targets.
Collectively, these studies provide evidence that cytotoxic effector
molecules, including GzmB and Prf1, can be modulated by NK
cell miRNAs. Since differences in 3 UTRs exist between human
and mouse GzmB and perforin, careful evaluation of each candidate miRNA in both species will be required to fully understand
its role in regulating NK cell cytotoxicity.
IFN-γ is a key immune cytokine produced by NK cells following activation. The regulation of its production is complex
and involves the integration of various signaling pathways (Vivier
et al., 2008) and multiple layers of regulation (Young, 1996). As one
form of regulation, IFN-γ is regulated post-transcriptionally via a
5 pseudoknot and 3 AU-rich elements, both of which can affect
the stability of the IFN-γ transcript (Khabar and Young, 2007).
Recently, miRNA-mediated regulation has also been reported.
However, due to the integrative nature of IFN-γ production, many
of these effects are indirect, instead mediating upstream signaling components. For example, signal transducer and activator of
transcription 4 (STAT4), a key mediator of IL-12-induced signals,
was reported to be targeted by miR-132, miR-212, and miR-200a
(Huang et al., 2011). In addition, lentiviral over-expression of
miR-181a/b has been reported to increase human NK cell IFN-γ
production after stimulation with IL-12 and IL-18 production
(Cichocki et al., 2011). However, these cells were cultured for
14 days in IL-15, transduction efﬁciency and subset biology was
not presented, and thus the alterations may be inﬂuenced by the
changes that result from long-term culture. In T cells, multiple
miRNAs, including the miR-17∼92 cluster (Jiang et al., 2011) and
miR-21 (Lu et al., 2011b) have been shown to regulate the decision between T helper type 1 (Th 1) and Th 2 lineages, which has
an indirect effect on IFN-γ production. Three miRNA families
have been found to speciﬁcally target IFN-γ or genes immediately upstream of its induction in NK cells: miR-155, miR-29, and
miR-15/16.
miR-155 was discovered to be the functional product of the
BIC non-coding RNA, which is highly expressed in human lymphoma samples (Eis et al., 2005). MiR-155 has been shown to
play a role in B cell (Rodriguez et al., 2007; Thai et al., 2007;
Vigorito et al., 2007; Teng et al., 2008), T cell (Kohlhaas et al.,
2009; O’Connell et al., 2010a), dendritic cell (Lu et al., 2011a),
and macrophage (O’Connell et al., 2007) biology, particularly in
the context of activation. While miR-155 is modestly expressed in
resting peripheral mouse and human NK cells, its expression is
markedly increased by activation with IL-18 (Fehniger et al., 2010;
Trotta et al., 2012; Sullivan, Leong, and Fehniger unpublished
data). Recently, Trotta et al. (2012) reported miR-155 as a positive regulator of NK IFN-γ production following IL-12 and IL-18
stimulation of human NK cells and lines that were transduced
with lentivirus to over-express miR-155. This effect was reported
to be mediated through direct repression of Src homology 2
domain-containing inositol-5-phosphatase 1 (SHIP-1; O’Connell
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et al., 2009), an established negative regulator of IFN-γ production
(Trotta et al., 2012). Additional studies clarifying the in vivo mechanistic role of miR-155, especially in the context of in vivo infection
and tumor models, will be of high interest. In addition, other
miR-155 questions still remain unanswered: is SHIP-1 the only
target of miR-155? Are there different mRNA targets before and
after cytokine activation? Thus, while miR-155 has a clear role in
regulating IFN-γ production, and targets SHIP-1, other roles for
miR-155 in NK cell effector function remain open to investigation.
The miR-29a/b/c family is moderately expressed in resting NK
cells (Fehniger et al., 2010), and has been shown to regulate the
IFN-γ pathway by two independent laboratories (Ma et al., 2011;
Steiner et al., 2011). However, these studies differ in their proposed
mechanisms of regulation. Indeed, the two studies identify two
unique targets for miR-29. Steiner et al. (2011) showed, through
an extensive miRNA screening approach, that at least in CD4+ T
cells, miR-29’s regulation of IFN-γ production was indirect, via
targeting Tbx21 (T-bet) and Eomes, two important transcription
factors that induce IFN-γ mRNA. In contrast, Ma et al. (2011)
created an in vivo sponge model targeting the miR-29 family. The
result of this “sponge,” which prevents miR-29 from binding to its
usual targets, resulted in increased IFN-γ protein production (Ma
et al., 2011). Further, through in vitro testing, the group showed
that this regulation of IFN-γ was direct, and that T-bet and Eomes
were not targets of miR-29. Additional in vitro studies by our lab in
293T cells utilizing luciferase sensor-plasmids failed to conﬁrm the
murine IFN-γ 3 UTR as a direct target of miR-29, while validating
targeting of T-bet and Eomes (Sullivan et al., 2012; Sullivan and
Fehniger, unpublished). Further study will be required to clarify
the precise role of miR-29 in IFN-γ regulation in NK cells using
NK cell-speciﬁc genetic models.
The miR-15/16 family is encoded from two distinct loci in the
genome, miR-15a/16-1 and miR-15b/16-2, which are processed
to three mature miRNAs: miR-15a, miR-15b, and miR-16. This
family has been implicated in the development or progression
of several malignancies, including chronic lymphocytic leukemia
(Klein et al., 2010; Iorio and Croce, 2012). Additionally, they have
been shown to regulate cell survival and cell cycle progression
through regulation of Bcl2 and cyclin D1, respectively (Cimmino
et al., 2005; Oﬁr et al., 2011). All members of the miR-15/16 family are highly expressed in NK cells, suggesting that transcription
operates from both loci (Fehniger et al., 2010). These family members are predicted through bioinformatic algorithms to target the
murine IFN-γ 3 UTR, which was conﬁrmed in vitro by luciferase
sensor-plasmid experiments (Sullivan et al., 2012). Furthermore,
mature miRNAs from this family are down-regulated in primary
NK cells after activation with IFN-γ stimulating conditions. While
these ﬁndings suggest that the miR-15/16 family of miRNAs may
be key players in regulating NK cell IFN-γ production, additional
studies utilizing in vitro and in vivo loss- and gain-of-function will
be required to deﬁne the non-redundant role of this miRNA family
on NK cell IFN-γ production.

NK CELL miRNAs IN DISEASE
Natural killer cells are primarily deﬁned by their role in preventing disease and malignancy through recognition of target cells
(Orange and Ballas, 2006), and a large and growing body of
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literature on the miRNA-mediated regulation of NK cell receptor
ligands on target cells has been extensively covered elsewhere (Elias
and Mandelboim, 2012). However, dysregulated NK cells can cause
or participate in a wide variety of diseases, including hemophagocytic lymphohistiocytosis (Filipovich, 2009), pre-eclampsia (Riley
and Yokoyama, 2008), atopy, and autoimmunity, among others.
Data for the role for NK cell-intrinsic miRNA in these diseases is
limited, but an important area of active investigation. For example, it was recently found that in patients with chronic fatigue
syndrome, certain highly expressed NK miRNAs, such as miR21, were signiﬁcantly decreased in NK cells (Brenu et al., 2012).
Most of the existing literature regarding the role of NK miRNAs
in disease focuses on NK cell malignancies. Rare cancers arising from NK cells can take multiple forms with various degrees
of aggression, from chronic NK cell lymphocytosis, to aggressive nasal-type NK/T cell lymphoma, to highly aggressive NK cell
leukemia/lymphoma (Ishida and Kwong, 2010; Watters et al., 2011;
Semenzato et al., 2012).
Several reports have shown dysregulated miRNA levels in NK
cell malignancies. Yamanaka et al. (2009) reported over-expression
of both miR-21 and/or miR-155 in malignant NK cell lines as well
as primary patient samples. The authors further linked miR-21 to
phosphatase and tensin homolog (PTEN) and miR-155 to SHIP-1,
two well known tumor regulators, the suppression of which could
enhance cancer progression (Yamanaka et al., 2009). In contrast,
Ng et al. (2011) showed that in nasal-type NK/T lymphomas, miRNAs (miR-26a/b, miR-28-5p, miR-101, miR-146a, miR-363) were
predominantly down-regulated. Whether or not this is an important biological difference between nasal-type NK/T lymphomas
and the more aggressive NK cell leukemia/lymphoma remains
to be established. Decreased expression of miR-146a was also
found to be a poor prognostic factor in NK/T lymphoma by Paik
et al. (2011). The authors suggest that this occurs via miR-146a
suppression of tumor necrosis factor receptor-associated factor
6 (TRAF6), which is a target of miR-146a. miRNAs produced
by Epstein–Barr virus (EBV) may be involved in the transformation leading to the aggressive NK cell lymphoma. Ramakrishnan
et al. (2011) proﬁled NK cell lymphoma cell lines, and found
that EBV-encoded miRNAs (BART-7, BART-9, BART-17-5p) were
abundantly expressed, and that loss of these miRNAs resulted in
reduced cell division rates. However, these intriguing results were
highly dependent on the cell line chosen, and require conﬁrmation
in additional cell lines as well as primary samples. Further studies
will also be required to determine the requirement, if any, for EBVencoded miRNAs in the pathogenesis of EBV-infected NK tumor
cells. In a recent study from the Caligiuri laboratory the mechanisms whereby chronic exposure to high levels of IL-15 may lead
to large granule lymphocyte (LGL) leukemia were deﬁned. Excessive IL-15 signals led to Myc-mediated suppression of miR-29b,
in turn leading to Dnmt3b over-expression and DNA hypermethylation (Mishra et al., 2012). The authors showed that miR-29b
inhibition directly led to increased LGL transformation in a cell
line system. Furthermore, using liposomal bortezomib (a proteasome inhibitor), the authors were able to dramatically enhance the
levels of miR-29b, which was correlated with decreased Dnmt3b
expression and disease-free survival in ICR-SCID mice that were
normally 100% susceptible to LGL leukemia. These studies directly
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implicate loss of miR-29b in causing LGL leukemia with rescue
of miR-29b levels resulting in resolution of disease. Thus, this
provides the rationale for studying miR-29 mimetics as a novel
miRNA-based therapy for this disease.
There remain many unanswered questions in how miRNA dysregulation may lead to disease. For each of the miRNAs putatively
involved in NK cell disease pathogenesis, it will be important to
study the role of these miRNAs in primary cells and model organisms using both genetic gain and loss of miRNA function in order
to address the mechanism of miRNA function. As of now, much
of the data for miRNA involvement in disease is correlative, but if
miRNA alterations are shown to cause or contribute to pathogenesis or disease progression, there exists great potential for targeting
using miRNA mimics or silencers in vivo.

miRNA TARGET DETERMINATION IN NK CELLS
miRNA biogenesis is regulated at multiple levels, and private components have been identiﬁed that may control individual miRNA
expression levels (Kim, 2005; Winter et al., 2009). Further, many
miRNAs exist in families, with closely related members that share
key binding speciﬁcity sequences, including the “seed” sequence,
from base pairs 2–8 (5 → 3 ) of the mature miRNA, that is the
major determinant of target speciﬁcity (Garcia et al., 2011). These
families of miRNAs are thought to cooperate in their regulation
of target genes, and thus loss-of-function models can be difﬁcult, as one must account for all expressed family members of a
given family. In order to avoid this complexity, miRNA “sponges”
that sequester whole miRNA families can be transgenically introduced; however, it is possible that introducing a foreign small RNA
sequence could have unintended or off-target consequences.
miRNAs can be computationally predicted to bind to hundreds of target mRNAs (Lewis et al., 2003), but these predictions
are prone to false positive and negatives, and thus it is critical to
biochemically and biologically validate predicted miRNA:mRNA
target interactions. In addition, multiple disparate mature miRNAs likely regulate the same mRNA via distinct and/or overlapping
3 UTR binding sites, and it remains unclear how these multiple
sites interact. A plethora of miRNA target determination tools
have become available over the past few years, including bioinformatic algorithms such as TargetScan1 , Ensembl MicroCosm2 , and
others (Wang, 2008). These tools are useful in developing initial
hypotheses about the role of individual miRNAs in cellular function, but have a high percentage of false positives (Neilson et al.,
2007; Sullivan, Leong, and Fehniger, unpublished data); i.e., many
“targets” determined by bioinformatic algorithms may not be true
targets in vitro or in vivo. An ostensibly straightforward molecular
biology experiment to determine if a gene is targeted by a miRNA
is to transduce a target cell type with the miRNA of interest, and
observe a down-regulation at a protein level via western blot or
equivalent method. However, this approach is complicated in NK
cells by the difﬁculty in reproducibly introducing foreign RNA into
resting NK cells, as well as off-target effects of miRNA that may
result in the observed repression being an indirect, rather than
direct effect. Therefore, though prediction methods and in vitro
1 http://www.targetscan.org/
2 http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/
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FIGURE 4 | Schema of Argonaute/RISC immunoprecipitation procedure and analysis.

transduction can be useful for hypothesis generation, they are surprisingly limited in their ability to validate in vivo miRNA:mRNA
interactions.
Besides the obvious beneﬁt of phenotype conﬁrmation, creation of a miRNA-knockout or transgenic mouse model grants the
opportunity to use a variety of techniques to conﬁrm individual
miRNA targeting of speciﬁc genes. Argonaute immunoprecipitation is one effective method of screening for the effects of an
individual miRNA on a speciﬁc cell type (Karginov et al., 2007;
Chi et al., 2009; Matkovich et al., 2011). In this method, both
total RNA and RNA immunoprecipitated using anti-Argonaute
(a component of the RISC) antibodies, and are sequenced
(using next-generation sequencing approaches) and aligned to the
genome (Figure 4). miRNA-knockout or miRNA-over-expressing
NK cells can be compared to WT NK cells for their RISC-bound
(Figure 1) RNA “proﬁle,” as well as their total RNA proﬁle. While
controversy still exists in the ﬁeld over the relative contribution
of miRNA to transcript degradation or translational inhibition
(Ambros, 2004; He and Hannon, 2004; Liu, 2008; Selbach et al.,
2008), a combination of assessing total RNA changes and RISCincorporation changes can determine, at a functional level, the
role of an individual miRNA in targeting. This technique has yet
to be applied to NK cells, and will likely unveil very interesting
ﬁndings.
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Predicted miRNA targeting of an mRNA can also be biochemically validated, most commonly using a luciferase“sensor plasmid”
reporter system. In this system, the 3 UTR of a putative target gene
is fused to luciferase. This construct is then transfected into a cell
line, such as HEK293T, while co-transfecting another vector that
over-expresses or inhibits the miRNA of interest. If a miRNA targets the 3 UTR of interest, this is experimentally measured by a
decrease in luciferase activity. This approach, while useful, has a
number of caveats, and it is important to be cognizant of potential
confounders in this system. Proper controls and veriﬁcations must
be included, including (1) validation of miRNA over-expression,
(2) use of a luciferase vector with no 3 UTR to determine “baseline” targeting of the vector, (3) normalization of the luciferase
signal to control for transfection efﬁciency differences between
different luciferase constructs, and (4) mutation of the putative
miRNA binding site in the 3 UTR in order to demonstrate that
loss of this predicted site results in loss of miRNA-mediated repression. The last issue, mutating the predicted binding site, is critical
to demonstrate a direct targeting event. In our experiments, the
psiCheck2 vector (Promega) has performed consistently and effectively. The use of a non-NK cell to evaluate a mRNA:miRNA
targeting interaction is a reasonable ﬁrst step in validating that
the miRNA targets the given mRNA. In fact, since some miRNAs
that are highly expressed in NK cells are not highly expressed in

February 2013 | Volume 4 | Article 44 | 9

“ﬁmmu-04-00044” — 2013/2/26 — 16:00 — page 9 — #9

Sullivan et al.

MicroRNA regulation of natural killer cells

293T cells, these miRNAs may be more easily over-expressed and
otherwise manipulated, allowing one to more easily observe the
effects of miRNA over-expression on that speciﬁc target. However, similar to most functional aspects of NK cell biology, it is
critical to validate a given miRNA:mRNA targeting event in primary NK cells, since there is the possibility that certain effects of
miRNAs require inducible machinery that is unique to NK cells.
This requires speciﬁc miRNA mouse genetic models or in vitro
mediated gain- and loss-of-function, paired with evaluation of
the speciﬁc miRNA-mediated phenotype in primary NK cells.

CONCLUSION
miRNAs are a class of non-coding RNAs that have increasingly
been shown to be critical to NK gene regulation. Recently, the
NK cell ﬁeld has become acquainted with the miRNA expression
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